These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2233 related articles for article (PubMed ID: 22728514)

  • 1. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.
    Vrieze A; Van Nood E; Holleman F; Salojärvi J; Kootte RS; Bartelsman JF; Dallinga-Thie GM; Ackermans MT; Serlie MJ; Oozeer R; Derrien M; Druesne A; Van Hylckama Vlieg JE; Bloks VW; Groen AK; Heilig HG; Zoetendal EG; Stroes ES; de Vos WM; Hoekstra JB; Nieuwdorp M
    Gastroenterology; 2012 Oct; 143(4):913-6.e7. PubMed ID: 22728514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota and SCFA in lean and overweight healthy subjects.
    Schwiertz A; Taras D; Schäfer K; Beijer S; Bos NA; Donus C; Hardt PD
    Obesity (Silver Spring); 2010 Jan; 18(1):190-5. PubMed ID: 19498350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.
    Vrieze A; Out C; Fuentes S; Jonker L; Reuling I; Kootte RS; van Nood E; Holleman F; Knaapen M; Romijn JA; Soeters MR; Blaak EE; Dallinga-Thie GM; Reijnders D; Ackermans MT; Serlie MJ; Knop FK; Holst JJ; van der Ley C; Kema IP; Zoetendal EG; de Vos WM; Hoekstra JB; Stroes ES; Groen AK; Nieuwdorp M
    J Hepatol; 2014 Apr; 60(4):824-31. PubMed ID: 24316517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time.
    de Groot P; Scheithauer T; Bakker GJ; Prodan A; Levin E; Khan MT; Herrema H; Ackermans M; Serlie MJM; de Brauw M; Levels JHM; Sales A; Gerdes VE; Ståhlman M; Schimmel AWM; Dallinga-Thie G; Bergman JJ; Holleman F; Hoekstra JBL; Groen A; Bäckhed F; Nieuwdorp M
    Gut; 2020 Mar; 69(3):502-512. PubMed ID: 31147381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition.
    Kootte RS; Levin E; Salojärvi J; Smits LP; Hartstra AV; Udayappan SD; Hermes G; Bouter KE; Koopen AM; Holst JJ; Knop FK; Blaak EE; Zhao J; Smidt H; Harms AC; Hankemeijer T; Bergman JJGHM; Romijn HA; Schaap FG; Olde Damink SWM; Ackermans MT; Dallinga-Thie GM; Zoetendal E; de Vos WM; Serlie MJ; Stroes ESG; Groen AK; Nieuwdorp M
    Cell Metab; 2017 Oct; 26(4):611-619.e6. PubMed ID: 28978426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher level of faecal SCFA in women correlates with metabolic syndrome risk factors.
    Teixeira TF; Grześkowiak Ł; Franceschini SC; Bressan J; Ferreira CL; Peluzio MC
    Br J Nutr; 2013 Mar; 109(5):914-9. PubMed ID: 23200109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal microbiota transfer may increase irritable bowel syndrome and inflammatory bowel diseases-associated bacteria.
    Konstantinov SR; Peppelenbosch MP
    Gastroenterology; 2013 Apr; 144(4):e19-20. PubMed ID: 23462124
    [No Abstract]   [Full Text] [Related]  

  • 8. Intestinal microbiota in inflammation and insulin resistance: relevance to humans.
    De Bandt JP; Waligora-Dupriet AJ; Butel MJ
    Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):334-40. PubMed ID: 21587065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects.
    Bouter K; Bakker GJ; Levin E; Hartstra AV; Kootte RS; Udayappan SD; Katiraei S; Bahler L; Gilijamse PW; Tremaroli V; Stahlman M; Holleman F; van Riel NAW; Verberne HJ; Romijn JA; Dallinga-Thie GM; Serlie MJ; Ackermans MT; Kemper EM; Willems van Dijk K; Backhed F; Groen AK; Nieuwdorp M
    Clin Transl Gastroenterol; 2018 May; 9(5):155. PubMed ID: 29799027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes.
    Utzschneider KM; Van de Lagemaat A; Faulenbach MV; Goedecke JH; Carr DB; Boyko EJ; Fujimoto WY; Kahn SE
    Obesity (Silver Spring); 2010 Sep; 18(9):1781-7. PubMed ID: 20379148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia?
    Brun JF; Aloulou I; Varlet-Marie E
    Clin Hemorheol Microcirc; 2004; 30(3-4):203-9. PubMed ID: 15258344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome.
    Ragab A; Abousamra NK; Higazy A; Saleh O
    Lab Hematol; 2008; 14(1):1-6. PubMed ID: 18403313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.
    Rajilić-Stojanović M; Biagi E; Heilig HG; Kajander K; Kekkonen RA; Tims S; de Vos WM
    Gastroenterology; 2011 Nov; 141(5):1792-801. PubMed ID: 21820992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28.
    Ji YS; Kim HN; Park HJ; Lee JE; Yeo SY; Yang JS; Park SY; Yoon HS; Cho GS; Franz CM; Bomba A; Shin HK; Holzapfel WH
    Benef Microbes; 2012 Mar; 3(1):13-22. PubMed ID: 22348905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans.
    Lyoussi B; Ragala MA; Mguil M; Chraibi A; Israili ZH
    Clin Exp Hypertens; 2005 May; 27(4):377-94. PubMed ID: 15921074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis.
    Sajjad A; Mottershead M; Syn WK; Jones R; Smith S; Nwokolo CU
    Aliment Pharmacol Ther; 2005 Aug; 22(4):291-9. PubMed ID: 16097995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome.
    Snel M; Sleddering MA; Pijl H; Nieuwenhuizen WF; Frölich M; Havekes LM; Romijn JA; Jazet IM
    Eur J Clin Nutr; 2010 Apr; 64(4):419-23. PubMed ID: 20179727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
    Zwirska-Korczala K; Konturek SJ; Sodowski M; Wylezol M; Kuka D; Sowa P; Adamczyk-Sowa M; Kukla M; Berdowska A; Rehfeld JF; Bielanski W; Brzozowski T
    J Physiol Pharmacol; 2007 Mar; 58 Suppl 1():13-35. PubMed ID: 17443025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women with and without metabolic disorder differ in their gut microbiota composition.
    Munukka E; Wiklund P; Pekkala S; Völgyi E; Xu L; Cheng S; Lyytikäinen A; Marjomäki V; Alen M; Vaahtovuo J; Keinänen-Kiukaanniemi S; Cheng S
    Obesity (Silver Spring); 2012 May; 20(5):1082-7. PubMed ID: 22293842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome.
    Müller MJ; Lagerpusch M; Enderle J; Schautz B; Heller M; Bosy-Westphal A
    Obes Rev; 2012 Dec; 13 Suppl 2():6-13. PubMed ID: 23107255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 112.